Back to library

Educational Wellness Information Only

This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.

Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.

Metabolic · Incretin

Tirzepatide

FDA-approved GLP-1/GIP dual agonist.

FDA-Approved

Plain-Language Label Highlights

Brand names: Mounjaro, Zepbound

What it's approved for

Type 2 diabetes (Mounjaro) and chronic weight management (Zepbound).

A weekly injection that acts like two gut hormones (GLP-1 and GIP) — lowering blood sugar and meaningfully reducing appetite and weight.

Boxed Warning

Thyroid C-cell tumor risk in rodents — do not use with personal/family history of medullary thyroid cancer or MEN 2.

Common side effects
  • Nausea
  • Diarrhea
  • Decreased appetite
  • Vomiting
  • Constipation
Serious risks to know
  • Pancreatitis
  • Gallbladder disease
  • Severe GI reactions
  • Acute kidney injury
  • Hypoglycemia with other diabetes drugs
Who should avoid or use with extra caution
  • Medullary thyroid cancer history
  • MEN 2 syndrome
  • Pregnancy (weight-loss use)

Educational summary of the FDA prescribing information. Not a substitute for the full label or medical advice. Always discuss with a licensed prescriber.

Mechanism of Action

A dual agonist of the GLP-1 and GIP receptors. The combined incretin action improves glucose control and produces greater weight loss than GLP-1 monotherapy in head-to-head trials.

Research Areas

Type 2 diabetes (Mounjaro)
Chronic weight management (Zepbound)
Sleep apnea in obesity (recent approval)

Common Research Protocols

Weekly subcutaneous clinical use

Stepwise dose escalation in approved indications.

Protocols summarized for educational reference from published research. Not dosing guidance.

Cited Research

[1]New England Journal of Medicine·2022

Tirzepatide once weekly for weight management (SURMOUNT-1)

Up to ~21% mean weight loss at 72 weeks at the highest dose.

Important Considerations

  • FDA-approved; requires prescription and physician oversight.
  • GI side effects are dose-limiting.
  • Compounded versions are not FDA-evaluated.

Explore more peptides

Educational Information Only — Not Medical Advice

All content on this page is for educational and informational purposes only. It is not medical advice, diagnosis, or treatment. We make no claims that any peptide can diagnose, treat, cure, or prevent any disease. Peptides discussed are not FDA-approved for the indications listed unless explicitly stated otherwise.

Always consult a licensed healthcare provider before beginning any wellness protocol. Statements have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability, eligibility, and pricing may vary.

Searching the library…

Ask the Library

Ask anything about peptides — answers come from our curated reference library with citations.

Find a pharmacy that carries Tirzepatide

Leave your details and a vetted partner pharmacy will reach out with availability and pricing.